Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE The tumorigenic role of BRAF(V600E) in the development of PTC was documented in thyroid-targeted BRAF(V600E) transgenic mice, and rat thyroid cells overexpressed with BRAF(V600E) suggested that BRAF(V600E) is an initiator of tumorigenesis and is required for tumor progression in PTC. 20230995

2010

dbSNP: rs121913377
rs121913377
0.100 GeneticVariation BEFREE Using gene set enrichment analysis and in vitro and in vivo functional studies, we identified and validated a B-Raf(V600E) gene set signature associated with tumor progression in PTCs. 20498063

2010

dbSNP: rs121913377
rs121913377
0.100 GeneticVariation BEFREE The tumorigenic role of BRAF(V600E) in the development of PTC was documented in thyroid-targeted BRAF(V600E) transgenic mice, and rat thyroid cells overexpressed with BRAF(V600E) suggested that BRAF(V600E) is an initiator of tumorigenesis and is required for tumor progression in PTC. 20230995

2010

dbSNP: rs121913529
rs121913529
0.050 GeneticVariation BEFREE Co-expression of Kras(G12V) and Braf(D631A) in mouse lung cells markedly enhances tumour initiation, a phenomenon mediated by Craf kinase activity, and effectively accelerates tumour progression when activated in advanced lung adenocarcinomas. 28783725

2017

dbSNP: rs121913529
rs121913529
0.050 GeneticVariation BEFREE To determine which KRAS effectors were responsible for tumor progression, we created four effector domain mutants (S35, G37, E38 and C40) in G12V-activated KRAS and expressed these alone or with BrafV600E in mouse lungs... 24489653

2014

dbSNP: rs121913529
rs121913529
0.050 GeneticVariation BEFREE Other organs such as pancreas, liver, and small intestine do not exhibit neoplastic progression within 6 weeks following K-Ras(G12D) activation and do not show a potent tumor suppressor response. 22532587

2012

dbSNP: rs121913529
rs121913529
0.050 GeneticVariation BEFREE We hypothesized that tumor progression was because of concomitant activation of the mitogen-activated protein kinase pathway downstream of Kras(G12D) expression promoting cell survival and that the therapeutic effect of PF-04691502 would be enhanced by combinatory inhibition of MEK using PD-0325901. 21632463

2011

dbSNP: rs121913529
rs121913529
0.050 GeneticVariation BEFREE The transformed phenotype of IOE(CMYC) cells was further enhanced in concert with KRAS(G12V)/BRAF(V600E) expression, as in vitro analyses indicated that IOE(CMYC) cells had undergone morphological and phenotypic changes characteristic of neoplastic progression. 21859834

2011

dbSNP: rs121434569
rs121434569
0.040 GeneticVariation BEFREE The EGFR resistance mutation T790M should be monitored at cancer progression. 31445213

2019

dbSNP: rs121434569
rs121434569
0.040 GeneticVariation BEFREE Liquid biopsies (LB) are used routinely in clinical practice in two situations for late stage non-small-cell lung cancer (NSCLC) patients, (i) at the initial diagnosis when looking for activating mutations in EGFR in the absence of analyzable tissue DNA and, (ii) during tumor progression on a tyrosine kinase inhibitor treatment to look for the resistance mutation T790M in EGFR. 29069959

2017

dbSNP: rs121434569
rs121434569
0.040 GeneticVariation BEFREE Finally, in the prospective series, SiRe detected 8.7% (4/46) of EGFR mutations at baseline and 42.9% (9/21) of EGFR p.T790M in patients at tumour progression. 28170370

2017

dbSNP: rs121434569
rs121434569
0.040 GeneticVariation BEFREE Detection of T790M with plasma DNA was correlated with EGFR mutation type, exon 19 deletions and tumor progression. 26577492

2016

dbSNP: rs351855
rs351855
0.030 GeneticVariation BEFREE Thus, our findings elucidate the molecular mechanism behind the genetic association of rs351855 with accelerated cancer progression and suggest that germline variants of cell-surface molecules that recruit STAT3 to the inner cell membrane are a significant risk for cancer prognosis and disease progression. 26675719

2015

dbSNP: rs351855
rs351855
0.030 GeneticVariation BEFREE This LOH involved the FGFR4-WT allele as frequently as the cancer progression-associated FGFR4-G388R polymorphic allele. 21037081

2010

dbSNP: rs758272654
rs758272654
0.030 GeneticVariation BEFREE In summary, the GNAS1 T393C SNP represents a genetic host factor for predicting tumor progression also in patients with MM; genotyping of this SNP may contribute to better define patients who could benefit from an early individualized therapy. 21156401

2010

dbSNP: rs758272654
rs758272654
0.030 GeneticVariation BEFREE The present study provides strong evidence to suggest that the GNAS1 T393C allele carrier status influences tumor progression and survival in gastric cancer with higher tumor stages and a worse outcome for C allele carriers. 20027678

2009

dbSNP: rs758272654
rs758272654
0.030 GeneticVariation BEFREE Kaplan-Meier curves for tumor progression, development of metastasis, and tumor-related death showed a significant association of the T393C polymorphism with outcome (5-year cancer-specific survival rates: TT, 91%; TC, 81%; CC, 69%; P = 0.015). 16467086

2006

dbSNP: rs351855
rs351855
0.030 GeneticVariation BEFREE Three other nonparametric linear rank-tests particularly suitable for investigating possible relations between G388R mutation and early cancer progression were also used. 14710228

2004

dbSNP: rs2273535
rs2273535
0.020 GeneticVariation BEFREE The single nucleotide polymorphism AURKA T91A (rs2273535) (Phe21Ile) has been identified as functional alternator of this kinase, the Ile allele is associated with the occurrence of chromosome segregation errors and tumor progression. 28647900

2018

dbSNP: rs2273535
rs2273535
0.020 GeneticVariation BEFREE For esophageal cancer, the AurkA Phe31-Ile polymorphism has previously been associated with tumor progression. 29560108

2018

dbSNP: rs3761548
rs3761548
0.020 GeneticVariation BEFREE Our study suggests that <i>FOXP3</i> polymorphism rs3761548 is associated with BC susceptibility in the Chinese and may be involved in tumor progression. 29731666

2018

dbSNP: rs1284806277
rs1284806277
MOK
0.020 GeneticVariation BEFREE Stable S100P knockdown CRC cell lines were established to elucidate the relationship between S100P expression and tumor progression in vitro and in vivo. 26975699

2016

dbSNP: rs3761548
rs3761548
0.020 GeneticVariation BEFREE Stratified data also revealed an association of homozygous mutant genotype with advanced stage of tumor in premenopausal women (OR = 4.56; 95% CI = 1.07-19.38; p = 0.04) with disease duration of <6 months (OR =  .10; 95% CI = 1.80-20.50; p = 0.002) suggestive of modulating effect of rs3761548 in tumor progression. 24338714

2014

dbSNP: rs762846821
rs762846821
0.020 GeneticVariation BEFREE We crossed IL-6(-/-) mice with Kras(G12D) mutant mice, which develop lung tumors after activation of mutant Kras(G12D), to investigate whether IL-6 inhibition contributes to tumor progression and survival time in vivo. 24260500

2013

dbSNP: rs752021744
rs752021744
0.020 GeneticVariation BEFREE Additionally, we tested efficacy of PD-0325901 in Kras(G12D-LSL) conditional GEMMs (genetically engineered mouse models) which are a valuable tool in translational research to study tumor progression. 22684718

2012